About Zyphar's Pharmaceutics Private Limited
Data last updated: 20 December 2025
Zyphar's Pharmaceutics Private Limited is a private limited company based in Pune, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 17 February 2006, the company has been in operation for over 20 years.
Registered with ROC Pune under CIN U24231PN2006PTC022042.
Capital: an authorised share capital of ₹4.95 Cr and a paid-up capital of ₹4.95 Cr. It is led by directors including Mahendra Champalal Jain and Rajeshkumar Champalal Jain.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: Office No. 102 & 103 Park Plaza First Floor Opp Kamala Nehru Park Erandwane, Pune, Maharashtra, India – 411004.
As per the financials filed for FY 2025, the company reported a revenue of ₹221.78 Cr, reflecting significant growth compared to the previous year.
The company has a workforce of approximately 146 employees as per the latest available data. Its group structure includes 2 subsidiaries.
As per MCA filings, the company has open charges of ₹20.75 Cr and satisfied charges of ₹6.89 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website zyphars.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressOffice No. 102 & 103 Park Plaza First Floor Opp Kamala Nehru Park Erandwane, Pune, Maharashtra, India – 411004
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Business Activity of Zyphar's Pharmaceutics Private Limited
Zyphar's Pharmaceutics Private Limited is engaged in the principal business activity of trade, with detailed activities including retail trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading | ********* |
Auditor Details of Zyphar's Pharmaceutics Private Limited
Zyphar's Pharmaceutics Private Limited is audited by Agrawal Dhand Motwani & Co. for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Agrawal Dhand Motwani & Co. | blur-value | blur-value | blur-value |
Board of Directors of Zyphar's Pharmaceutics Private Limited
Zyphar's Pharmaceutics Private Limited is currently managed by 4 directors, with 2 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mahendra Champalal Jain | Director | 17 Feb 2006 | 20 Years 4 Months | Current |
|
Rajeshkumar Champalal Jain
Also directs:
Anutej Vastunirman Llp, Sinsan Lifesciences Private Limited, Xion Pharmaceuticals Private Limited and 5 more
|
Managing Director | 17 Feb 2006 | 20 Years 4 Months | Current |
|
Roshan Champalal Jain
Also directs:
Sinsan Lifesciences Private Limited, Xion Pharmaceuticals Private Limited, Sinsan Pharmaceuticals Private Limited and 4 more
|
Director | 17 Feb 2006 | 20 Years 4 Months | Current |
| Kapil Ganeshmal Sonigara | Director | 17 Feb 2006 | 20 Years 4 Months | Current |
Financials of Zyphar's Pharmaceutics Private Limited FY 2024 filings available
Zyphar's Pharmaceutics Private Limited reported revenue of ₹221.78 Cr (up 283% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Zyphar's Pharmaceutics Private Limited
As of FY 2024, Zyphar's Pharmaceutics Private Limited's shareholding pattern shows 57.74% by promoters, 42.26% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Zyphar's Pharmaceutics Private Limited
Zyphar's Pharmaceutics Private Limited has 2 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Zyphar's Pharmaceutics Private Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Sta-Co Nutra Products Private Limited | U15490PN2013PTC148501 |
**.**%
|
| Zyphar's Biopharmaceuticals Private Limited | U24299PN2021PTC206752 |
**.**%
|
Showing major subsidiaries. Total: 2.
Charges & Borrowings of Zyphar's Pharmaceutics Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Sep 2025 | Others | ₹2 Cr | Open |
| 22 Oct 2019 | Others | ₹1 Cr | Open |
| 11 Jun 2019 | Others | ₹1 Cr | Open |
| 06 Feb 2018 | Others | ₹50 Lakh | Open |
| 10 Jun 2016 | Others | ₹25 Lakh | Open |
Total charge records: 10 View all charges
Employees and EPFO Compliance at Zyphar's Pharmaceutics Private Limited
Zyphar's Pharmaceutics Private Limited has a workforce of 146 employees as of Apr 08, 2025.
Employee Count & EPFO Data of Zyphar's Pharmaceutics Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Zyphar's Pharmaceutics Private Limited
GSTIN & GST Filing Data of Zyphar's Pharmaceutics Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Zyphar's Pharmaceutics Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Zyphar's Pharmaceutics Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Zyphar's Pharmaceutics Private Limited
MSME Payment Delays by Zyphar's Pharmaceutics Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Zyphar's Pharmaceutics Private Limited
Subsidiaries & Group Companies of Zyphar's Pharmaceutics Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Zyphar's Pharmaceutics Private Limited with ownership details.
MCA Filings & Documents of Zyphar's Pharmaceutics Private Limited
MCA Filings & Documents of Zyphar's Pharmaceutics Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Zyphar's Pharmaceutics Private Limited
Frequently Asked Questions about Zyphar's Pharmaceutics Private Limited
Zyphar's Pharmaceutics Private Limited is an active private limited company in the pharma sector based in Pune, Maharashtra, India. It was incorporated on 17 February 2006 (20+ years old) and is registered under CIN U24231PN2006PTC022042. The company has 146 employees.
Zyphar's Pharmaceutics Private Limited reported revenue of ₹221.78 Cr for FY 2025 (up 283.00% YoY).
The current directors of Zyphar's Pharmaceutics Private Limited are:
The primary industry of Zyphar's Pharmaceutics Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Zyphar's Pharmaceutics Private Limited can be reached at the registered office: Office No. 102 & 103 Park Plaza First Floor Opp Kamala Nehru Park Erandwane, Pune, Maharashtra, India – 411004, or through the website zyphars.com.
The authorised capital is ₹4.95 Cr, and the paid-up capital is ₹4.95 Cr.